TABLE OF CONTENTS
Volume 78, Issue 6 (December 2005)
Pharmacogenetics and Genomics |
Pharmacokinetics and Drug Disposition |
Pharmacodynamics and Drug Action |
Clinical Trials |
Notes of the American Society for Clinical Pharmacology and Therapeutics |
Editorial board |
Author Index
Commentaries
Drug-metabolizing enzymes: Evidence for clinical utility of pharmacogenomic tests
Tommy Andersson PhD, David A. Flockhart MD, PhD, David B. Goldstein PhD, Shiew-Mei Huang PhD, Deanna L. Kroetz PhD, Patrice M. Milos PhD, Mark J. Ratain MD and Kenneth Thummel PhD
Clin Pharmacol Ther 78: 559-581; doi:10.1016/j.clpt.2005.08.013
In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: Qualitative relationships, quantitative predictions, and the rank-order approach
R. Scott Obach PhD, Robert L. Walsky BSc, Karthik Venkatakrishnan PhD, J. Brian Houston PhD and Larry M. Tremaine PhD
Clin Pharmacol Ther 78: 582-592; doi:10.1016/j.clpt.2005.09.004
Pharmacogenetics and Genomics
Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment
Séverine Crettol, Jean-Jacques Déglon MD, Jacques Besson MD, Marina Croquette-Krokkar MD, Isabelle Gothuey MD, Robert Hämmig MD, Martine Monnat MD, Hardy Hüttemann MD, Pierre Baumann PhD and Chin B. Eap PhD
Clin Pharmacol Ther 78: 593-604; doi:10.1016/j.clpt.2005.08.011
Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5
Stéphane J. Mouly MD, PhD, Chris Matheny PhD, Mary F. Paine PhD, Glenn Smith PhD, Jatinder Lamba PhD, Vishal Lamba MS, Susan N. Pusek MPH, Erin G. Schuetz PhD, Paul W. Stewart PhD and Paul B. Watkins MD
Clin Pharmacol Ther 78: 605-618; doi:10.1016/j.clpt.2005.08.014
Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists
Melih O. Babaoglu MD, Banu Bayar MD, A. Sukru Aynacioglu MD, Reinhold Kerb MD, Huseyin Abali MD, Ismail Celik MD and Atila Bozkurt MD, PhD
Clin Pharmacol Ther 78: 619-626; doi:10.1016/j.clpt.2005.08.015
Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: Evidence from clinical and pharmacokinetic data
Matthias Schwab MD, Ulrich Klotz PhD, Ute Hofmann PhD, Elke Schaeffeler PhD, Andreas Leodolter MD, Peter Malfertheiner MD and Gerhard Treiber MD
Clin Pharmacol Ther 78: 627-634; doi:10.1016/j.clpt.2005.08.017
Pharmacogenomics of responsiveness to interferon IFN-
treatment in multiple sclerosis: A genetic screen of 100 type I interferon-inducible genes
Stephen Cunningham PhD, Colin Graham PhD, Michael Hutchinson MD, Aidan Droogan MD, Killian O'Rourke MD, Chris Patterson PhD, Gavin McDonnell MD, Stanley Hawkins FRCP and Koen Vandenbroeck PhD
Clin Pharmacol Ther 78: 635-646; doi:10.1016/j.clpt.2005.08.018
CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia
Shinichi Inomata MD, Atsushi Nagashima PhD, Fumio Itagaki PhD, Masato Homma PhD, Masuhiro Nishimura PhD, Yoshiko Osaka MD, Kazuhiko Okuyama MD, Einosuke Tanaka PhD, Takako Nakamura PhD, Yukinao Kohda PhD, Shinsaku Naito PhD, Masayuki Miyabe MD and Hidenori Toyooka MD
Clin Pharmacol Ther 78: 647-655; doi:10.1016/j.clpt.2005.08.020
Arg16 homozygosity of the 2-adrenergic receptor improves the outcome after 2-agonist tocolysis for preterm labor
Ruth Landau MD, Michel A. Morales, Stylianos E. Antonarakis MD, DSc, FACMG, Jean-Louis Blouin PhD and Richard M. Smiley MD, PhD
Clin Pharmacol Ther 78: 656-663; doi:10.1016/j.clpt.2005.08.021
Pharmacokinetics and Drug Disposition
Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers
Rob E. Aarnoutse PharmD, PhD, Johanneke Kleinnijenhuis MSc, Peter P. Koopmans MD, PhD, Daan J. Touw PharmD, PhD, Jaap Wieling PhD, Yechiel A. Hekster PharmD, PhD and David M. Burger PharmD, PhD
Clin Pharmacol Ther 78: 664-674; doi:10.1016/j.clpt.2005.09.001
Pharmacodynamics and Drug Action
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses
Gary A. Herman MD, Cathy Stevens BSN, Kristien Van Dyck PhD, Arthur Bergman PhD, Bingming Yi PhD, Marina De Smet PhD, Karen Snyder MS, Deborah Hilliard MS, Michael Tanen BS, Wesley Tanaka PhD, Amy Q. Wang PhD, Wei Zeng MS, Donald Musson PhD, Gregory Winchell PhD, Michael J. Davies PhD, Steven Ramael MD, Keith M. Gottesdiener MD and John A. Wagner MD, PhD
Clin Pharmacol Ther 78: 675-688; doi:10.1016/j.clpt.2005.09.002
Clinical Trials
Smoking reduction treatment with 4-mg nicotine gum: A double-blind, randomized, placebo-controlled study
Anil Batra MD, Karl Klingler MD, Björn Landfeldt MA, Hubertus M. Friederich MD, Åke Westin MSc and Tobias Danielsson BSc
Clin Pharmacol Ther 78: 689-696; doi:10.1016/j.clpt.2005.08.019
Notes of the American Society for Clinical Pharmacology and Therapeutics
A message from the ASCPT membership committee chairperson
John T. Sullivan MD Chairperson
Clin Pharmacol Ther 78: 697-698; doi:10.1016/j.clpt.2005.10.001
Editorial board
Editorial Board for index
Clin Pharmacol Ther 78: 711; doi:10.1016/S0009-9236(05)00504-7
Copyright page for index
Clin Pharmacol Ther 78: 712; doi:10.1016/S0009-9236(05)00505-9
